Life sciences clauses

Copyright © 2026 LexisNexis

This subtopic includes a selection of definitions and standard commercial clauses for use in agreements in the life sciences sector.

For boilerplate commercial clauses and standard definitions which may be used in life sciences agreements, see: Boilerplate clauses—overview and Definitions—overview.

For a summary of the law, guidance and practice in relation to the execution of documents, along with standard execution clauses, see: Execution—overview.

Life sciences definitions

For examples of definitions which are frequently used in life sciences agreements, see Precedents:

  1. •

    Applicable Laws and Medical Product Law definitions—life sciences

  2. •

    Clinical trial laws definition—life sciences

  3. •

    Derivatives definition—life sciences

  4. •

    EU Notified Body and UK Approved Body definition—life sciences

  5. •

    Exploit definition—life sciences

  6. •

    Good Clinical Practice (GCP) definition—life sciences

  7. •

    Good Laboratory Practice (GLP) definition—life sciences

  8. •

    Governmental Entity definition—life sciences

  9. •

    Industry Practice definition—life sciences

  10. •

    Material definition—life sciences

  11. •

    Principal investigator (PI) definition—life sciences

  12. •

    Product definition—life sciences

  13. •

    Progeny definition—life sciences

  14. •

    Regulatory Documentation definition—life sciences

  15. •

    Regulatory Approvals definition—life sciences

  16. •

    Regulatory Authority definition—life sciences

Intellectual property

Intellectual

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Existing user? Sign-in TAKE A FREE TRIAL
Powered by Lexis+®
Latest Life Sciences News

DHSC consults on expanding medicines data reporting regime

The Department of Health and Social Care (DHSC) has published its 2025 annual review of the Health Service Products (Provision and Disclosure of Information) Regulations 2018 and the Health Service Medicines (Price Control Penalties and Price Control Appeals Amendment) Regulations 2018, and is consulting on proposed amendments to strengthen medicines reimbursement, supply oversight and compliance across the UK. Published on 10 February 2026 and covering the period July 2022 to June 2025, the review concludes that the objectives of the regulations remain appropriate but that changes are needed to improve the effectiveness of NHS reimbursement arrangements, enhance management of medicines shortages and ensure better value for money for taxpayers.

Life Sciences weekly highlights—12 February 2026

This week's edition of Life Sciences weekly highlights includes analysis of the Supreme Court’s decision in Emotional Perception AI Ltd v Comptroller-General of Patents, Designs and Trade Marks, in which the court held that an artificial neural network system is not excluded from patentability as a ‘program for a computer…as such’, aligning UK law more closely with European Patent Office jurisprudence. Also included, is news that the DHSC has opened a consultation on changes to the statutory scheme for branded medicines pricing to align with the voluntary scheme, DHSC also released its finding and recommendations on the operation of the Medicines and Medical Devices Act 2021 in its five-year report and it has also opened a consultation on proposed amendments to strengthen medicines reimbursement, supply oversight and compliance further to its 2025 annual review of the Health Service Products 2018 regulations. Further developments include NICE launching the National HealthTech Access Programme, MHRA updating its pharmacovigilance requirements for UK authorised products further to Commission Implementing Regulation (EU) No 520/2012 (CIR 520/2012), the Notified Bodies industry publishing a letter addressing proposed cybersecurity amendments to the medical devices regulations, the adoption of the international standards ICH M15 guideline for model-informed drug development, the EMA launching a consultation on making Annex 15 GMP qualification and validation guidelines mandatory, and the EFPIA published proposals to strengthen EU pharmaceutical competitiveness; among other stories.

EFPIA updates European hospitality thresholds scorecard for pharmaceutical industry

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published its updated thresholds for meals and drinks, setting out maximum hospitality limits permitted across member countries. In some jurisdictions, higher limits are conditional on a minimum scientific programme duration. The scorecard shows varying limits ranging from €32 per meal in Ukraine to €135 in Iceland, with some countries requiring minimum scientific activity durations and different VAT treatment approaches. For example, Belgium permits hospitality of €45 for lunch and €90 for dinner (incl. VAT), subject to a minimum of six hours of scientific activities. France, Germany, Spain and Italy set per-meal limits of approximately €70–75 (incl. VAT), while Ireland sets a limit of €90 per meal (incl. VAT). In the UK, a maximum of £75 plus VAT and gratuities is permitted only in exceptional circumstances.

DHSC publishes statutory 5-year review of Medicines and Medical Devices Act 2021

The Department of Health and Social Care (DHSC) has published its statutory five-year report on the operation of the Medicines and Medical Devices Act 2021 (MMDA 2021), concluding that while the UK’s legislative frameworks for human medicines, veterinary medicines and medical devices remain effective and protective of public and animal health, aspects of the legislation would benefit from consolidation, restructuring and reform of the delegated powers and procedural requirements governing how regulations are made and amended.

View Life Sciences by content type :  
News
Practice notes
Precedents
Q&As

Popular documents

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

If a rentcharge is shown as being informally exonerated on title information, does this apply to the

If a rentcharge is shown as being informally exonerated on title information, does this apply to the current registered owner? Or does the informal exoneration only apply to the parties to the document which informally exonerated the rentcharge?This Q&A considers the situation where, at some

Strike out—making an application to strike out a statement of case

Strike out—making an application to strike out a statement of caseA strike out order can be made either following an application by the parties or on the court's own initiative. This Practice Note deals with the scenario of the order being made following a party's application.Making an application

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements[Insert addressee details]Dear [insert name][It is our understanding that [insert name of prospective employee] [was an employee of yours between the dates of [insert dates as appropriate] OR is a current employee of
What is the difference between an appeal and a review?

What is the difference between an appeal and a review?

What is the difference between an appeal and a review?What is an appeal?An appeal in insolvency proceedings is no different to an appeal in normal litigation. An appeal will be allowed only if the appeal court is satisfied that the decision of the lower court was 'wrong' or 'unjust because of a

If a rentcharge is shown as being informally exonerated on title information, does this apply to the

If a rentcharge is shown as being informally exonerated on title information, does this apply to the

If a rentcharge is shown as being informally exonerated on title information, does this apply to the current registered owner? Or does the informal exoneration only apply to the parties to the document which informally exonerated the rentcharge?This Q&A considers the situation where, at some

Strike out—making an application to strike out a statement of case

Strike out—making an application to strike out a statement of case

Strike out—making an application to strike out a statement of caseA strike out order can be made either following an application by the parties or on the court's own initiative. This Practice Note deals with the scenario of the order being made following a party's application.Making an application

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements

Template for regulatory references given by SMCR firms and disclosure requirements[Insert addressee details]Dear [insert name][It is our understanding that [insert name of prospective employee] [was an employee of yours between the dates of [insert dates as appropriate] OR is a current employee of